United Medical is to be the exclusive distributor and sales representative for Pharmaxis' Bronchitol (mannitol) in Brazil. Under the terms of the agreement, United Medical will be responsible for sales and marketing, pricing, warehousing, distribution and patient support. The company will file a marketing approval application with the Brazilian regulatory agency (ANVISA) based on Bronchitol's Australian approval, which is expected to take up to 18 months. Pharmaxis will receive milestone payments ahead of Bronchitol's approval in Brazil.
Bronchitol is a precision spray-dried form of mannitol, delivered to the lungs by a specially-designed portable inhaler, for the treatment of cystic fibrosis. The product is approved for marketing for patients aged over six years in Australia and for patients aged 18 years and over throughout the EU.